Literature DB >> 15471883

Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer.

George C Katsafanas1, Bernard Moss.   

Abstract

Transcription of the DNA genome of vaccinia virus occurs in the cytoplasm and is temporally programmed by early, intermediate, and late stage-specific transcription factors in conjunction with a viral multisubunit RNA polymerase. The RNA polymerase, capping enzyme, and three factors (VITF-1, VITF-2, and VITF-3) are sufficient for in vitro transcription of a DNA template containing an intermediate stage promoter. Vaccinia virus intermediate transcription factor (VITF)-1 and -3 are virus-encoded, whereas VITF-2 was partially purified from extracts of uninfected HeLa cells. Using purified and recombinant viral proteins, we showed that the HeLa cell factor was required for transcription of linear or nicked circular templates but not of super coiled DNA. HeLa cell polypeptides of approximately 110 and 66 kDa copurified with VITF-2 activity through multiple chromatographic steps. The polypeptides were separated by SDS-polyacrylamide gel electrophoresis and identified by mass spectrometry as Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and p137, recently named cytoplasmic activation/proliferation-associated protein-1. The co-purification of the two polypeptides with transcription-complementing activity was confirmed with specific antibodies, and their association with each other was demonstrated by affinity chromatography of tagged recombinant forms. Furthermore, recombinant G3BP and p137 expressed individually or together in mammalian or bacterial cells complemented the activity of the viral RNA polymerase and transcription factors. The involvement of cellular proteins in transcription of intermediate stage genes may regulate the transition between early and late phases of vaccinia virus replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471883     DOI: 10.1074/jbc.M411033200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Purification, crystallization and preliminary X-ray diffraction of the G3BP1 NTF2-like domain.

Authors:  Tina Vognsen; Ingvar Rúnar Möller; Ole Kristensen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-12-21

2.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Authors:  Jeong Heo; Caroline J Breitbach; Anne Moon; Chang Won Kim; Rick Patt; Mi Kyung Kim; Yu Kyung Lee; Sung Yong Oh; Hyun Young Woo; Kelley Parato; Julia Rintoul; Theresa Falls; Theresa Hickman; Byung-Geon Rhee; John C Bell; David H Kirn; Tae-Ho Hwang
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

4.  Defining the Role of Stress Granules in Innate Immune Suppression by the Herpes Simplex Virus 1 Endoribonuclease VHS.

Authors:  Hannah M Burgess; Ian Mohr
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

5.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

6.  Cancer: Tumour-fighting virus homes in.

Authors:  Evanthia Galanis
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

7.  Microtubule-dependent association of AKAP350A and CCAR1 with RNA stress granules.

Authors:  Elena Kolobova; Andrey Efimov; Irina Kaverina; Arun K Rishi; John W Schrader; Amy-Joan Ham; M Cecilia Larocca; James R Goldenring
Journal:  Exp Cell Res       Date:  2008-12-03       Impact factor: 3.905

8.  Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters.

Authors:  Zhilong Yang; Liliana Maruri-Avidal; Jerry Sisler; Carey A Stuart; Bernard Moss
Journal:  Virology       Date:  2013-10-03       Impact factor: 3.616

9.  Oncolytic vaccinia virotherapy for endometrial cancer.

Authors:  Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

10.  Cytoplasmic RNA Granules and Viral Infection.

Authors:  Wei-Chih Tsai; Richard E Lloyd
Journal:  Annu Rev Virol       Date:  2014-11       Impact factor: 10.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.